Nanexa Signs Novo Nordisk License Deal Worth Up to €1.165 Billion

Is Nanexa receiving €1.165 billion upfront?

No. Nanexa said €615 million combines the upfront payment with development and regulatory milestones, while the remaining potential payments are sales milestones; the exact upfront amount was not disclosed.

Orbitrum Investor Impact

What did Nanexa license to Novo Nordisk?

Novo received global exclusive rights to use PharmaShell for certain peptide drugs in obesity, type 2 diabetes and other cardiometabolic indications across up to five development programs targeting monthly or quarterly dosing.

Why does the deal matter for Nanexa investors?

The agreement creates potential upfront, milestone and royalty income from Nanexa's drug-delivery platform while Novo assumes leadership of global development and commercialization. Nanexa will also receive low single-digit royalties on global net sales of products developed under the agreement.

How did Nanexa shares react to the agreement?

Nanexa shares were up about 122% in early trading on September 25, 2026, after the licensing agreement was announced.

What remains uncertain about the €1.165 billion deal value?

Much of the headline value depends on future development, regulatory and sales milestones. The announcement did not disclose the standalone upfront payment, individual milestone amounts or a product-launch timetable.

What happens next under the Novo Nordisk agreement?

Novo will lead development and commercialization of the covered programs, while Nanexa's additional payments depend on achieving development, regulatory and sales milestones and royalties require future product sales.